Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
News|Articles|October 10, 2025
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
Author(s)Rose McNulty
Fact checked by: Maggie L. Shaw
Explore the implications of the Most Favored Nation Order on US drug pricing reform and its potential impact on patient access and innovation.
Advertisement
Advertisement
Drug pricing reform is a complex undertaking, and developments related to the recent Most Favored Nation (MFN) executive order give insight into how the initiative may fit into broader drug pricing reform in the US. This was the basis of discussion at a webinar hosted by MJH Life Sciences® titled “Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”
Related to this article
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
Advertisement
Advertisement